FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2606317367> ?p ?o ?g. }

• W2606317367 endingPage "41507" @default.
• W2606317367 startingPage "41498" @default.
• W2606317367 abstract "// Pin-Fang He 1, 2, * , Jing-Dong Zhou 4, * , Dong-Ming Yao 3, * , Ji-Chun Ma 1, 2 , Xiang-Mei Wen 1, 2 , Zhi-Hui Zhang 4 , Xin-Yue Lian 4 , Zi-Jun Xu 1, 2 , Jun Qian 4 and Jiang Lin 1, 2 1 Laboratory Center, Affiliated People’s Hospital of Jiangsu University, Zhenjiang 212002, Jiangsu, P.R. China 2 The Key Lab of Precision Diagnosis and Treatment of Zhenjiang City, Zhenjiang 212002, Jiangsu, P.R. China 3 Department of Clinical Laboratory, Affiliated People’s Hospital of Jiangsu University, Zhenjiang 212002, Jiangsu, P.R. China 4 Department of Hematology, Affiliated People’s Hospital of Jiangsu University, Zhenjiang 212002, Jiangsu, P.R. China * These authors contributed equally to this work Correspondence to: Jiang Lin, email: linjiangmail@sina.com Jun Qian, email: qianjun0007@hotmail.com Keywords: acute myeloid leukemia (AML), decitabine, elderly patient, systematic review, meta-analysis Received: December 08, 2016      Accepted: April 11, 2017      Published: April 19, 2017 ABSTRACT Elderly patients with acute myeloid leukemia (AML) have limited treatment options concerned about their overall fitness and potential treatment related mortality. Although a number of clinical trials demonstrated benefits of decitabine treatment in elderly AML patients, the results remains controversial. A meta-analysis was performed to evaluate efficacy and safety of decitabine in treatment of elderly AML patients. Eligible studies were identified from PubMed, Web of Science, Embase and Cochrane Library. Nine published studies were included in the meta-analysis, enrolling 718 elderly AML patients. The efficacy outcomes were complete remission (CR), overall response rate (ORR) and overall survival (OS). Safety was evaluated based on treatment related grades 3–4 adverse events (AEs) and early death (ED) rate. Pooled estimates with 95% confidence interval (CI) for CR, ORR and OS were 27% (95% CI 19%–36%), 37% (95% CI 28%–47%) and 8.09 months (95% CI 5.77–10.41), respectively. The estimated treatment related early death (ED) incidences were within 30-days 7% (95% CI 2%–11%) and 60-days 17% (95% CI 11%–22%), respectively. Thrombocytopenia was the most common grades 3–4 AEs. Subgroup analyses of age, cytogenetics risk, AML type and bone marrow blast percentage showed no significant differences of treatment response to decitabine. In conclusion, decitabine is an effective and well-tolerated therapeutic alternative with acceptable side effects in elderly AML patients." @default.
• W2606317367 created "2017-04-28" @default.
• W2606317367 creator A5002926270 @default.
• W2606317367 creator A5014048532 @default.
• W2606317367 creator A5015150059 @default.
• W2606317367 creator A5025218228 @default.
• W2606317367 creator A5037332032 @default.
• W2606317367 creator A5045245977 @default.
• W2606317367 creator A5083862643 @default.
• W2606317367 creator A5084645019 @default.
• W2606317367 creator A5086352195 @default.
• W2606317367 date "2017-04-19" @default.
• W2606317367 modified "2023-10-14" @default.
• W2606317367 title "Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis" @default.
• W2606317367 cites W1585096943 @default.
• W2606317367 cites W1606162789 @default.
• W2606317367 cites W1867200963 @default.
• W2606317367 cites W1895158254 @default.
• W2606317367 cites W1963919702 @default.
• W2606317367 cites W1981898318 @default.
• W2606317367 cites W1982035148 @default.
• W2606317367 cites W1983306434 @default.
• W2606317367 cites W1984814872 @default.
• W2606317367 cites W1988758777 @default.
• W2606317367 cites W1995789257 @default.
• W2606317367 cites W2008682627 @default.
• W2606317367 cites W2028627376 @default.
• W2606317367 cites W2040855010 @default.
• W2606317367 cites W2041356430 @default.
• W2606317367 cites W2047536451 @default.
• W2606317367 cites W2057652101 @default.
• W2606317367 cites W2063260586 @default.
• W2606317367 cites W2075578916 @default.
• W2606317367 cites W2078892073 @default.
• W2606317367 cites W2081391009 @default.
• W2606317367 cites W2082365047 @default.
• W2606317367 cites W2087584460 @default.
• W2606317367 cites W2098923148 @default.
• W2606317367 cites W2101296870 @default.
• W2606317367 cites W2101892777 @default.
• W2606317367 cites W2106084333 @default.
• W2606317367 cites W2109150359 @default.
• W2606317367 cites W2117954942 @default.
• W2606317367 cites W2119649565 @default.
• W2606317367 cites W2122782605 @default.
• W2606317367 cites W2128168358 @default.
• W2606317367 cites W2139948141 @default.
• W2606317367 cites W2146493115 @default.
• W2606317367 cites W2149058047 @default.
• W2606317367 cites W2149361505 @default.
• W2606317367 cites W2159507916 @default.
• W2606317367 cites W2160968219 @default.
• W2606317367 cites W2192207543 @default.
• W2606317367 cites W2277597240 @default.
• W2606317367 cites W2300461615 @default.
• W2606317367 cites W2494648386 @default.
• W2606317367 cites W2549790759 @default.
• W2606317367 cites W2588681363 @default.
• W2606317367 cites W4376595466 @default.
• W2606317367 cites W999678125 @default.
• W2606317367 doi "https://doi.org/10.18632/oncotarget.17241" @default.
• W2606317367 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5522197" @default.
• W2606317367 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28489568" @default.
• W2606317367 hasPublicationYear "2017" @default.
• W2606317367 type Work @default.
• W2606317367 sameAs 2606317367 @default.
• W2606317367 citedByCount "51" @default.
• W2606317367 countsByYear W26063173672017 @default.
• W2606317367 countsByYear W26063173672018 @default.
• W2606317367 countsByYear W26063173672019 @default.
• W2606317367 countsByYear W26063173672020 @default.
• W2606317367 countsByYear W26063173672021 @default.
• W2606317367 countsByYear W26063173672022 @default.
• W2606317367 countsByYear W26063173672023 @default.
• W2606317367 crossrefType "journal-article" @default.
• W2606317367 hasAuthorship W2606317367A5002926270 @default.
• W2606317367 hasAuthorship W2606317367A5014048532 @default.
• W2606317367 hasAuthorship W2606317367A5015150059 @default.
• W2606317367 hasAuthorship W2606317367A5025218228 @default.
• W2606317367 hasAuthorship W2606317367A5037332032 @default.
• W2606317367 hasAuthorship W2606317367A5045245977 @default.
• W2606317367 hasAuthorship W2606317367A5083862643 @default.
• W2606317367 hasAuthorship W2606317367A5084645019 @default.
• W2606317367 hasAuthorship W2606317367A5086352195 @default.
• W2606317367 hasBestOaLocation W26063173671 @default.
• W2606317367 hasConcept C104317684 @default.
• W2606317367 hasConcept C126322002 @default.
• W2606317367 hasConcept C143998085 @default.
• W2606317367 hasConcept C150194340 @default.
• W2606317367 hasConcept C17744445 @default.
• W2606317367 hasConcept C185592680 @default.
• W2606317367 hasConcept C190727270 @default.
• W2606317367 hasConcept C191935318 @default.
• W2606317367 hasConcept C199539241 @default.
• W2606317367 hasConcept C2776478404 @default.
• W2606317367 hasConcept C2778729363 @default.
• W2606317367 hasConcept C2780235182 @default.
• W2606317367 hasConcept C512399662 @default.

• next